Zentalis Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
Company Research
Source: GlobeNewswire
NEW YORK and SAN DIEGO, April 07, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the closing of its initial public offering of 10,557,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,377,000 additional shares, at a public offering price of $18.00 per share, for total gross proceeds of approximately $190.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the shares of common stock in the offering were sold by Zentalis. The Company’s common stock began trading on the Nasdaq Global Market on April 3, 2020 under the ticker symbol “ZNTL.” Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as joint book-running managers for the off
Show less
Read more
Impact Snapshot
Event Time:
ZNTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZNTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZNTL alerts
High impacting Zentalis Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ZNTL
News
- Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law FirmGlobeNewswire
- Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its price target lowered by analysts at Guggenheim from $12.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of AzenosertibGlobeNewswire
ZNTL
Earnings
- 11/12/24 - Beat
ZNTL
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form 4
- 11/13/24 - Form 3
- ZNTL's page on the SEC website